Cyrano Therapeutics has successfully closed a $12.8M Series A round in November 2020 led by Remiges Ventures and Lumira Ventures. The funds will be used to complete a Phase 2 clinical trial of the company’s lead product, CYR-064, in the U.S. and Europe. As part of the financing, Taka Koda of Remiges Ventures and Gerry Brunk of Lumira Ventures have joined the company’s board of directors.
Remiges Ventures is a US and Japan based venture fund that invests in early to mid-stage biopharma companies. Stage creates new companies based on intellectual properties from the Japanese academia. Remiges also has its own research activities conducted through scientific collaborations to validate hypotheses with top researchers, academic institutions and CROs. The team is connected with KOLs, serial entrepreneurs, key consultants and pharma BD people in various therapeutics areas and they actively participate in creating value for its portfolio companies.
Lumira executes a consistent, proven investment strategy as a lead investor and active partner with our portfolio companies. We focus on companies whose products offer transformative (not incremental) improvements to patient health outcomes, and the promise of dramatic reductions in the cost of healthcare delivery. Our Canadian heritage helps us “skate to where the puck is going to be,” investing in the new science and clinical insights that we expect will be driving the next decade of patient care.